Loading
A phase 3 trial of Disitamab vedotin, Pembrolizumab, Gemcitabine, Cisplatin and Carboplatin in bladder & urothelial cancer, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 is a phase 3 interventional study registered as NCT05911295 by Seagen, a wholly owned subsidiary of Pfizer, with 412 participants enrolled, started 2023-09-22 and due to reach its primary completion in 2027-01-29. Interventions recorded: disitamab vedotin, pembrolizumab, gemcitabine, cisplatin and carboplatin.
Shares Disitamab vedotin, Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
Shares RemeGen, Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.